TY - JOUR
T1 - Macrophage mannose receptor CD206 targeting of fluoride-18 labeled mannosylated dextran
T2 - A validation study in mice
AU - Andriana, Putri
AU - Fair-Makela, Ruth
AU - Liljenback, Heidi
AU - Karna, Salli
AU - Iqbal, Imran
AU - Makrypidi, Konstantina
AU - Rajander, Johan
AU - Pirmettis, Ioannis
AU - Li, Xiang-Guo
AU - Jalkanen, Sirpa
AU - Saraste, Antti
AU - Salmi, Marko
AU - Roivainen, Anne
PY - 2024/7
Y1 - 2024/7
N2 - Purpose: Aluminum fluoride-18-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-conjugated mannosylated dextran derivative (Al[
18F]F-NOTA-D10CM) is a new tracer for PET imaging. We report here on in vitro and in vivo validation of the tracer’s ability to target the macrophage mannose receptor CD206. Methods: First, the uptake of intravenously (i.v.) administered Al[
18F]F-NOTA-D10CM was compared between wild-type (WT) and CD206
−/− knockout (KO) mice. C57BL/6N mice were injected with complete Freund’s adjuvant (CFA) in the left hind leg and the uptake of Al[
18F]F-NOTA-D10CM after i.v. or intradermal (i.d.) injection was studied at 5 and 14 days after CFA induction of inflammation. Healthy C57BL/6N mice were studied as controls. Mice underwent PET/CT on consecutive days with [
18F]FDG, i.v. Al[
18F]F-NOTA-D10CM, and i.d. Al[
18F]F-NOTA-D10CM. After the last imaging, Al[
18F]F-NOTA-D10CM was i.v. injected for an ex vivo biodistribution study and autoradiography of inflamed tissues. Blood plasma samples were analyzed using high-performance liquid chromatography. To evaluate the specificity of Al[
18F]F-NOTA-D10CM binding, an in vitro competitive displacement study was performed on inflamed tissue sections using autoradiography. CD206 expression was assessed by immunohistochemical staining. Results: Compared with WT mice, the uptake of Al[
18F]F-NOTA-D10CM was significantly lower in several CD206
−/− KO mice tissues, including liver (SUV 8.21 ± 2.51 vs. 1.06 ± 0.16, P < 0.001) and bone marrow (SUV 1.63 ± 0.37 vs. 0.22 ± 0.05, P < 0.0001). The uptake of i.v. injected Al[
18F]F-NOTA-D10CM was significantly higher in inflamed ankle joint (SUV 0.48 ± 0.13 vs. 0.18 ± 0.05, P < 0.0001) and inflamed foot pad skin (SUV 0.41 ± 0.10 vs. 0.04 ± 0.01, P < 0.0001) than in the corresponding tissues in healthy mice. The i.d.-injected Al[
18F]F-NOTA-D10CM revealed differences between CFA-induced lymph node activation and lymph nodes in healthy mice. Ex vivo γ-counting, autoradiography, and immunohistochemistry supported the results, and a decrease of ~ 80% in the binding of Al[
18F]F-NOTA-D10CM in the displacement study with excess NOTA-D10CM confirmed that tracer binding was specific. At 60 min after i.v. injection, an average 96.70% of plasma radioactivity was derived from intact Al[
18F]F-NOTA-D10CM, indicating good in vivo stability. The uptake of Al[
18F]F-NOTA-D10CM into inflamed tissues was positively associated with the area percentage of CD206-positive staining. Conclusion: The uptake of mannosylated dextran derivative Al[
18F]F-NOTA-D10CM correlated with CD206 expression and the tracer appears promising for inflammation imaging. Graphical abstract: (Figure presented.)
AB - Purpose: Aluminum fluoride-18-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-conjugated mannosylated dextran derivative (Al[
18F]F-NOTA-D10CM) is a new tracer for PET imaging. We report here on in vitro and in vivo validation of the tracer’s ability to target the macrophage mannose receptor CD206. Methods: First, the uptake of intravenously (i.v.) administered Al[
18F]F-NOTA-D10CM was compared between wild-type (WT) and CD206
−/− knockout (KO) mice. C57BL/6N mice were injected with complete Freund’s adjuvant (CFA) in the left hind leg and the uptake of Al[
18F]F-NOTA-D10CM after i.v. or intradermal (i.d.) injection was studied at 5 and 14 days after CFA induction of inflammation. Healthy C57BL/6N mice were studied as controls. Mice underwent PET/CT on consecutive days with [
18F]FDG, i.v. Al[
18F]F-NOTA-D10CM, and i.d. Al[
18F]F-NOTA-D10CM. After the last imaging, Al[
18F]F-NOTA-D10CM was i.v. injected for an ex vivo biodistribution study and autoradiography of inflamed tissues. Blood plasma samples were analyzed using high-performance liquid chromatography. To evaluate the specificity of Al[
18F]F-NOTA-D10CM binding, an in vitro competitive displacement study was performed on inflamed tissue sections using autoradiography. CD206 expression was assessed by immunohistochemical staining. Results: Compared with WT mice, the uptake of Al[
18F]F-NOTA-D10CM was significantly lower in several CD206
−/− KO mice tissues, including liver (SUV 8.21 ± 2.51 vs. 1.06 ± 0.16, P < 0.001) and bone marrow (SUV 1.63 ± 0.37 vs. 0.22 ± 0.05, P < 0.0001). The uptake of i.v. injected Al[
18F]F-NOTA-D10CM was significantly higher in inflamed ankle joint (SUV 0.48 ± 0.13 vs. 0.18 ± 0.05, P < 0.0001) and inflamed foot pad skin (SUV 0.41 ± 0.10 vs. 0.04 ± 0.01, P < 0.0001) than in the corresponding tissues in healthy mice. The i.d.-injected Al[
18F]F-NOTA-D10CM revealed differences between CFA-induced lymph node activation and lymph nodes in healthy mice. Ex vivo γ-counting, autoradiography, and immunohistochemistry supported the results, and a decrease of ~ 80% in the binding of Al[
18F]F-NOTA-D10CM in the displacement study with excess NOTA-D10CM confirmed that tracer binding was specific. At 60 min after i.v. injection, an average 96.70% of plasma radioactivity was derived from intact Al[
18F]F-NOTA-D10CM, indicating good in vivo stability. The uptake of Al[
18F]F-NOTA-D10CM into inflamed tissues was positively associated with the area percentage of CD206-positive staining. Conclusion: The uptake of mannosylated dextran derivative Al[
18F]F-NOTA-D10CM correlated with CD206 expression and the tracer appears promising for inflammation imaging. Graphical abstract: (Figure presented.)
KW - Fluorine-18
KW - Inflammation
KW - Macrophage mannose receptor CD206
KW - Mannosylated dextran
KW - Pet/ct
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=aboakademi&SrcAuth=WosAPI&KeyUT=WOS:001191081900001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s00259-024-06686-x
DO - 10.1007/s00259-024-06686-x
M3 - Article
C2 - 38532026
SN - 1619-7070
VL - 51
SP - 2216
EP - 2228
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 8
ER -